Clinical <i>ERG</i> break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience
Use of clinical ERG FISH assays may help confirm prostatic origin in the setting of localized or metastatic carcinoma showing poor differentiation or transdifferentiation and thus help determine the correct diagnosis and direct appropriate clinical management for such patients.
Authors
- Arul M. Chinnaiyan (ORCID: https://orcid.org/0000-0001-9282-3415)
- Robert Humble (ORCID: https://orcid.org/0000-0002-0509-9674)
- Bryan L. Betz
- Annette S. Kim (ORCID: https://orcid.org/0000-0002-8699-2439)
- Aiko Iwata‐Otsubo (ORCID: https://orcid.org/0000-0001-9378-3961)
- Jeffrey L. Myers (ORCID: https://orcid.org/0000-0001-8247-3028)
- Noah A. Brown (ORCID: https://orcid.org/0000-0001-9151-5912)
- Lina Shao (ORCID: https://orcid.org/0000-0002-6650-1698)
- Saravana M. Dhanasekaran (ORCID: https://orcid.org/0000-0002-0489-2224)
- Radha Paturu
- Hong Xiao
- Chen Yi Yang (ORCID: https://orcid.org/0000-0002-5547-3150)
- Rohit Mehra
Institutions
- Howard Hughes Medical Institute (US)
- University of Michigan (US)
- Michigan Medicine (US)
- Michigan Center for Translational Pathology (US)
- Michigan Cancer Research Consortium (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1093/ajcp/aqaf128
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00